Rosa & Co CEO, Dr. Ron Beaver Presents "Systems Pharmacology: First Principles to Effective Practice" in the Plenary Session of the Integrating Pharmacometrics Summit
San Carlos, CA, November 13, 2013 --(PR.com)-- Rosa & Co. LLC, a drug development advisory firm with expertise in drug-disease modeling and simulation, announced that Dr. Ron Beaver, CEO, presented a plenary session talk at the Hanson Wade Integrating Pharmacometrics Summit (October 21st -23rd 2013), Munich, Germany, entitled “Accomplishments and Challenges in Systems Pharmacology, from First Principles to Effective Practice.” Dr. Beaver discussed the volume of modeling experience in the pharmaceutical industry, the growing adoption of a quantitative systems pharmacology approach, and strategies for broad organizational integration. He also discussed strategies for positioning modeling, including: how to support drug development decisions; how to think about “value” and judge “quality”; dealing with skepticism; and setting projects up for success. He described how Rosa has applied these approaches systematically in its PhysioPD™ practice.
“It was exciting to participate with pharmaceutical companies and regulatory authorities and to hear their accounts of increasing successes and efficiencies gained by including quantitative modeling research approaches across company pipelines,” said Sharan Pagano, Rosa’s Vice President, Scientific Alliances. “We were pleased to be the expertise partner at this Conference and to share our perspective, gained from a decade of experience in growing our practice, on modeling processes, and the impact of modeling on the pharmaceutical industry.”
About Rosa
Rosa helps clients with their critical decisions – from preclinical through clinical development – with the creation and use of mathematical models that simulate normal and disease physiology, drug action, patient variability, and trial outcomes. To address the full spectrum of R&D related challenges, Rosa offers customized approaches: classic pharmacokinetic/pharmacodynamic (PK/PD) models and Rosa’s innovative PhysioPD™ models. With these capabilities, Rosa’s clients participate in customized model creation, testing, and research simulations, retain the models, and acquire the ability to perform model research to inform decisions and better understand implications for their drug development programs. Rosa’s staff has unparalleled professional experience in applying modeling and simulation to accelerate drug development and have completed hundreds of engagements with clients in virtually all therapeutic areas. The Rosa team is unique in its breadth and depth of disease area experience, including metabolic diseases, oncology, inflammation, immune dysfunction, CNS, dermatology, and antibacterial/antiviral biology. For more information, visit www.rosaandco.com.
“It was exciting to participate with pharmaceutical companies and regulatory authorities and to hear their accounts of increasing successes and efficiencies gained by including quantitative modeling research approaches across company pipelines,” said Sharan Pagano, Rosa’s Vice President, Scientific Alliances. “We were pleased to be the expertise partner at this Conference and to share our perspective, gained from a decade of experience in growing our practice, on modeling processes, and the impact of modeling on the pharmaceutical industry.”
About Rosa
Rosa helps clients with their critical decisions – from preclinical through clinical development – with the creation and use of mathematical models that simulate normal and disease physiology, drug action, patient variability, and trial outcomes. To address the full spectrum of R&D related challenges, Rosa offers customized approaches: classic pharmacokinetic/pharmacodynamic (PK/PD) models and Rosa’s innovative PhysioPD™ models. With these capabilities, Rosa’s clients participate in customized model creation, testing, and research simulations, retain the models, and acquire the ability to perform model research to inform decisions and better understand implications for their drug development programs. Rosa’s staff has unparalleled professional experience in applying modeling and simulation to accelerate drug development and have completed hundreds of engagements with clients in virtually all therapeutic areas. The Rosa team is unique in its breadth and depth of disease area experience, including metabolic diseases, oncology, inflammation, immune dysfunction, CNS, dermatology, and antibacterial/antiviral biology. For more information, visit www.rosaandco.com.
Contact
Rosa & Co LLC
Sharan Pagano
978-995-2805
http://www.rosaandco.com
Sharan Pagano
978-995-2805
http://www.rosaandco.com
Contact
Categories